October 24, 2016 08:15 AM EDT

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold

John Carroll

Editor & Founder

Nagging fears that Aduro Biotech’s cancer vaccine CRS-207 could trigger serious Listeria infections mushroomed into a severe setback on Monday morning as the biotech reported …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

New Lis­te­ria fears spot­light­ed as Aduro’s CRS-207 is slapped with par­tial hold

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test